AxoGen, Inc. cash flow to debt ratio of 1.20% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

AxoGen, Inc.'s free cash flow has decreased 26.76K% from $11.00K last year to $-2.93M, signaling decreasing performance

AxoGen, Inc.'s debt to equity ratio is 0.08, which means that the company's assets are healthy financed, signaling financial stability.

AxoGen, Inc.'s debt has decreased relative to shareholder equity from 0.66 last year to 0.08 today, signaling strengthened financials

AxoGen, Inc. has a net debt to EBITDA ratio of 167.09x, which exceeds the 3.00x threshold, indicating high leverage and potential financial risk

AxoGen, Inc.'s interest coverage ratio is -1.02, which means that the company struggles to meet interest obligations, signaling financial risk.

AxoGen, Inc.'s profit margin has decreased (151.12%) in the last year from -5.32% to -13.36%, signaling decreasing performance

AxoGen, Inc.'s short-term assets of $120.42M exceed its short-term liabilities of $23.56M

AxoGen, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

AxoGen, Inc.'s return on equity of -17.88%, is lower than 15.00%, indicating bad performance

AxoGen, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

AxoGen, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

AxoGen, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

AxoGen, Inc. has negative free cash flow, indicating cash burn

AxoGen, Inc.'s yearly earnings has decreased 57.60% since last year from $-9.96M to $-15.70M, signaling decreasing performance

AxoGen, Inc.'s yearly revenue has increased 20.21% since last year from $187.34M to $225.21M, signaling increasing performance

ROIC -4.65% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

AxoGen, Inc.'s 3-year revenue CAGR of 17.57% is positive, indicating growing revenue over the past 3 years

AxoGen, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

AxoGen, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

AxoGen, Inc. has insufficient data to evaluate this check.

AxoGen, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

AxoGen, Inc. is overvalued relative to its fair value price of 0.35 based on EBITDA multiple model

AxoGen, Inc. has an EV/EBITDA ratio of 13.67Kx, which exceeds the 20.00x threshold, indicating the stock may be overvalued relative to its operating earnings

AxoGen, Inc. has insufficient data to evaluate this check.

AxoGen, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

AxoGen, Inc. has a price-to-book ratio of 10.04x, which exceeds the 5.00x threshold, indicating the stock may be overvalued relative to its book value

AxoGen, Inc. has a price-to-sales ratio of 10.24x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue